title: The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial.
abstract: Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25.
authors.affiliation: Cancer Epidemiology Research Program (CERP), Catalan Institute of Oncology (Institut Català d'Oncologia-ICO) and Bellvitge Biomedical Research Institute, Avenida Gran Via 199-203, L’Hospitalet de Llobregat, Barcelona, Spain. admincerp@iconcologia.net
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Bosch
authors.forename: Silvia
authors.initials: S
authors.lastname: de Sanjose
authors.forename: Xavier
authors.initials: X
authors.lastname: Castellsague
mesh_terms: D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000276:immunology*; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*
chemical_list: D053918:Papillomavirus Vaccines